{"id":54080,"date":"2023-06-30T11:44:17","date_gmt":"2023-06-30T10:44:17","guid":{"rendered":"https:\/\/www.btitrainingcenter.com\/efficacy-of-plasma-rich-in-growth-factors-prgf-in-stage-1-neurotrophic-keratitis\/"},"modified":"2026-09-16T12:56:20","modified_gmt":"2026-09-16T11:56:20","slug":"efficacy-of-plasma-rich-in-growth-factors-prgf-in-stage-1-neurotrophic-keratitis","status":"publish","type":"post","link":"https:\/\/www.btitrainingcenter.com\/pt-pt\/efficacy-of-plasma-rich-in-growth-factors-prgf-in-stage-1-neurotrophic-keratitis\/","title":{"rendered":"Efficacy of Plasma Rich in Growth Factors (PRGF) in Stage 1 Neurotrophic Keratitis"},"content":{"rendered":"

[vc_row content_text_aligment=”left” row_background_lines=”no”][vc_column][vc_column_text]<\/p>\n

Abstract<\/h3>\n
\n
\n

Background\/aims: \u00a0<\/strong>Neurotrophic keratitis (NK) is a neurodegenerative disease that can lead to corneal hypoesthesia, decreased tear production, and epitheliopathy. Based on the severity of ocular surface damage, NK is classified into 3 stages. Stage 1 NK is characterized by superficial punctate keratopathy, tear film instability, and reduced corneal sensation. The therapeutic efficacy of PRGF eye drops for NK stages 2 and 3 has been previously reported. In this study, we evaluated the efficacy and safety of autologous PRGF eye drops in improving corneal sensitivity and other ocular surface clinical signs in patients with stage 1 NK.<\/p>\n

Methods:\u00a0<\/strong>Retrospective chart review.<\/p>\n

Results:\u00a0<\/strong>26 eyes of 15 stage 1 NK patients (seven males, eight females), aged 76.3 \u00b1 12.1 years, were included in the study. The mean treatment duration was 2 \u00b1 1.8 months. With PRGF treatment, corneal sensitivity increased from 2.8 to 4.5 cm in 53.8% (14\/26) (p < 0.01), TBUT increased from 3.6 to 5.0 s in 69.2% (18\/26) (p < 0.01), and Schirmer score increased from 13.7 to 16.8 mm in 80.7% (21\/26) of treated eyes (p < 0.01). Similarly, an improvement in corneal staining (punctate epithelial erosions) and MMP-9 levels was seen in 80.7% (n = 21) and 65.4% (n = 17) of treated eyes, respectively. BCVA improvement was seen in 26.9% of treated eyes (n = 7).<\/p>\n

Conclusions:\u00a0<\/strong>This study demonstrates the effective role of PRGF therapy in recovering corneal sensation and tear film function and in the healing of corneal erosions in stage 1 NK patients.<\/p>\n<\/div>\n

Keywords:\u00a0<\/strong>Neurotrophic keratitis; Ocular surface disease; Plasma rich in growth factors.<\/p>\n<\/div>\n

[\/vc_column_text][vc_empty_space][vc_column_text]<\/p>\n

Figures<\/h3>\n

[\/vc_column_text][vc_empty_space][\/vc_column][\/vc_row][vc_row content_text_aligment=”center”][vc_column]

\n\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t<\/div>\n<\/div>[vc_empty_space height=”50px”][\/vc_column][\/vc_row][vc_row][vc_column]\n Descarregar artigo<\/span>\n <\/a>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Res Sq [Preprint]. 2023 Jun 30:rs.3.rs-3040369.<\/strong>
\nNeurotrophic keratitis (NK) is a neurodegenerative disease that can lead to corneal hypoesthesia, decreased tear production, and epitheliopathy. Based on the severity of ocular surface damage, NK is classified into 3 stages. Stage 1 NK is characterized by superficial punctate keratopathy, tear film instability, and reduced corneal sensation. The therapeutic efficacy of PRGF eye drops for NK stages 2 and 3 has been previously reported. In this study, we evaluated the efficacy and safety of autologous PRGF eye drops in improving corneal sensitivity and other ocular surface clinical signs in patients with stage 1 NK.<\/p>\n","protected":false},"author":2002,"featured_media":54045,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[158],"tags":[],"class_list":["post-54080","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicina-regenerativa-pt-pt"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.btitrainingcenter.com\/pt-pt\/wp-json\/wp\/v2\/posts\/54080","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.btitrainingcenter.com\/pt-pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.btitrainingcenter.com\/pt-pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/pt-pt\/wp-json\/wp\/v2\/users\/2002"}],"replies":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/pt-pt\/wp-json\/wp\/v2\/comments?post=54080"}],"version-history":[{"count":1,"href":"https:\/\/www.btitrainingcenter.com\/pt-pt\/wp-json\/wp\/v2\/posts\/54080\/revisions"}],"predecessor-version":[{"id":54081,"href":"https:\/\/www.btitrainingcenter.com\/pt-pt\/wp-json\/wp\/v2\/posts\/54080\/revisions\/54081"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/pt-pt\/wp-json\/wp\/v2\/media\/54045"}],"wp:attachment":[{"href":"https:\/\/www.btitrainingcenter.com\/pt-pt\/wp-json\/wp\/v2\/media?parent=54080"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/pt-pt\/wp-json\/wp\/v2\/categories?post=54080"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/pt-pt\/wp-json\/wp\/v2\/tags?post=54080"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}